Overview

Study to Evaluate the Safety and Efficacy of a Monoclonal Antibody Cocktail for the Prevention of COVID-19

Status:
Not yet recruiting

Trial end date:
2023-08-01

Target enrollment:

Participant gender:

Summary

This is a Phase 2/3, randomized, double-blind, placebo-controlled, multi-center study to evaluate the safety, tolerability, and efficacy of ADM03820 to prevent symptomatic COVID-19 in adult subjects (≥ 18 years of age).

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Ology Bioservices

Collaborator:

Enabling Biotechnologies (EB)